DAX22.407 +0,6%ESt505.156 -0,3%Top 10 Crypto12,41 +2,3%Dow40.373 +0,4%Nas17.386 +0,1%Bitcoin83.409 +0,1%Euro1,1400 -0,2%Öl64,44 -1,8%Gold3.309 -1,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Tesla A1CX3T Deutsche Bank 514000 Lufthansa 823212 RENK RENK73 Mercedes-Benz Group (ex Daimler) 710000 Siemens Energy ENER6Y BASF BASF11 BYD A0M4W9 Porsche PAG911 Amazon 906866 Plug Power A1JA81 Deutsche Telekom 555750 Volkswagen (VW) vz. 766403
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX höher -- Wall Street uneins -- PayPal enttäuscht beim Umsatz -- Deutsche Bank mit mehr Umsatz -- Porsche senkt Prognose -- Palantir, Rheinmetall, Plug Power, Lufthansa, BASF im Fokus
Top News
S&P 500-Wert Eli Lilly-Aktie: So viel Gewinn hätte ein Investment in Eli Lilly von vor einem Jahr eingefahren S&P 500-Wert Eli Lilly-Aktie: So viel Gewinn hätte ein Investment in Eli Lilly von vor einem Jahr eingefahren
Dow Jones 30 Industrial-Papier IBM-Aktie: So viel Gewinn hätte eine IBM-Investition von vor 5 Jahren eingebracht Dow Jones 30 Industrial-Papier IBM-Aktie: So viel Gewinn hätte eine IBM-Investition von vor 5 Jahren eingebracht
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Europäische Aktien bieten Grund für Optimismus. Ihre Aussichten könnten langfristig besser sein als für die erfolgsverwöhnten US-Titel. DWS informiert

Eli Lilly Aktie

NeuKaufenVerkaufen
Eli Lilly Aktien-Sparplan
775,60 EUR +5,20 EUR +0,68 %
STU
882,48 USD +5,29 USD +0,60 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.730,04 Mrd. EUR

KGV65,91Div. Rendite0,67%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN858560

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS5324571083

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolLLY

Eli Lilly Aktien News

DatumMeistgelesen
EN, Eli LillyLilly confirms date and conference call for first-quarter 2025 financial results announcement
PR NewswireLilly confirms date and conference call for first-quarter 2025 financial results announcement
PR NewswireLilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial
Wer­bungEli Lilly-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
EN, Eli LillyLilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial
EN, Eli LillyStatement: Lilly has no affiliation with hims & hers
PR NewswireLilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels
EN, Eli LillyLilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels
EN, Eli LillyLilly’s statement about the CHMP opinion issued for donanemab
PR NewswireLillyDirect platform expands to facilitate access to Alzheimer's disease care
EN, Eli LillyLillyDirect platform expands to facilitate access to Alzheimer's disease care
PR NewswireLilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
EN, Eli LillyLilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
EN, Eli LillyLilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
PR NewswireLilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
EN, Eli LillyLilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis
PR NewswireLilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis
EN, Eli LillyLilly to participate in Leerink Partners Global Healthcare Conference
PR NewswireLilly to participate in Leerink Partners Global Healthcare Conference
PR NewswireLilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhi...
EN, Eli LillyLilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion
PR NewswireLilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion
PR NewswireLilly launches additional Zepbound vial doses and offers new savings for self-pay patients
EN, Eli LillyLilly launches additional Zepbound vial doses and offers new savings for self-pay patients
EN, Eli LillyLilly to participate in TD Cowen's 45th Annual Health Care Conference
PR NewswireLilly to participate in TD Cowen's 45th Annual Health Care Conference
PR NewswireMost patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
EN, Eli LillyMost patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
EN, Eli LillyMost patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
PR NewswireLilly reports full Q4 2024 financial results and provides 2025 guidance
EN, Eli LillyLilly reports full Q4 2024 financial results and provides 2025 guidance
EN, Eli LillyLilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement
PR NewswireLilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement
PR NewswireFDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
EN, Eli LillyFDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
EN, Eli LillyLilly provides update on 2024 revenue guidance, announces 2025 revenue guidance
PR NewswireLilly provides update on 2024 revenue guidance, announces 2025 revenue guidance
EN, Eli LillyLilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
PR NewswireLilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
EN, Eli LillyLilly to participate in J.P. Morgan Healthcare Conference
PR NewswireLilly to participate in J.P. Morgan Healthcare Conference
Wer­bung

Eli Lilly News

Eli Lilly News: auf dieser Seite finden Sie alle Eli Lilly News und Nachrichten zur Eli Lilly Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Eli Lilly News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Eli Lilly News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.